The implanted ePOWER patch stimulated in-situ production of bioactive extracellular vesicles, significantly reducing infarct size to approximately 10% and improving left ventricular ejection fraction in a rat model of myocardial infarction.
Does the ePOWER bioelectronic patch increase in situ production of bioactive extracellular vesicles and improve cardiac repair in preclinical models of myocardial infarction?
A programmable bioelectronic patch (ePOWER) significantly enhances in-situ production of therapeutic extracellular vesicles, offering a potential new strategy for myocardial infarction repair.
p-value: p=<0.0001
Current myocardial infarction (MI) treatment strategies remain challenged in suboptimal pharmacokinetics and potential adverse effects. Here we present a bioelectronic interface capable of producing on-demand abundant bioactive extracellular vesicles (EVs) near the MI area for in-situ localized treatment. The technology, termed electroactive patch for wirelessly and controllable EV generation (ePOWER), leverages wireless bioelectronic patch to stimulate embedded electrosensitive macrophages, actively modulating the biosynthesis of EVs and enabling EV production with high programmability to be delivered directly to the MI area. ~2400% more bioactive EVs were produced per cell under our ePOWER system. When surgically implanted, we demonstrate the therapeutic potential of in-situ EV production system to alleviate MI symptoms and improve cardiac function. This programmable ePOWER technology enables in-situ production of therapeutically rich EVs, thus reducing the need for exogenous cell expansion platforms and dedicated delivery, holding promise as a therapeutic all-in-one platform to treat various diseases. Myocardial infarction treatment strategies remain challenged in effectiveness. Here we present a bioelectronic interface capable of producing on-demand abundant bioactive extracellular vesicles near the disease area for in situ localized treatment.
Fu et al. (Tue,) conducted a other in Myocardial infarction. ePOWER patch (electroactive patch for wirelessly and controllable EV generation) vs. Untreated MI control and aspirin treatment was evaluated on Infarct size and left ventricular ejection fraction (LVEF) (p=<0.0001). The implanted ePOWER patch stimulated in-situ production of bioactive extracellular vesicles, significantly reducing infarct size to approximately 10% and improving left ventricular ejection fraction in a rat model of myocardial infarction.